Skip to main content

Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations







The Review on Antimicrobial Resistance
Chaired by Jim O’Neill

December 2014 









The UK Prime Minister announced a Review on Antimicrobial Resistance in July,
calling for ideas to bring this growing threat under control. This is the Review
team’s first paper, where we demonstrate that there could be profound health

and macroeconomic consequences for the world, especially in emerging economies,
if antimicrobial resistance (AMR) is not tackled.



We believe that this crisis can be avoided. The cost of taking action can be small
if we take the right steps soon. And the benefits will be large and long-lasting
especially for emerging economies, including the so-called BRIC nations, who
will need to make improved investments in their health infrastructure and build
industries that leapfrog to the next generation of innovation.



Defining the specific steps needed is what our sponsors the UK Prime Minister and
the Wellcome Trust set us off to do: by the summer of 2016, we will recommend

a package of actions that we think should be agreed internationally. To do this,
over the course of our Review we want to explore the following five themes,
starting with this paper.




  1. The impact of antimicrobial resistance on the world’s economy if the
    problem is not tackled.




  2. How we can change our use of antimicrobial drugs to reduce the rise
    of resistance, including the game-changing potential of advances

    in genetics, genomics and computer science.




  3. How we can boost the development of new antimicrobial drugs.




  4. The potential for alternative therapies to disrupt the rise in resistance
    and how these new ideas can be boosted.




  5. The need for coherent international action that spans drugs regulation,
    and drugs use across humans, animals and the environment.



We approach our goals with a blank sheet of paper and open minds. We want to hear
from bright and innovative minds across all countries and disciplines, starting with
the hard-earned experience of physicians, healthcare workers and their patients. 



Popular posts from this blog

Elizabeth Holmes Discusses Theranos at WSJDLive 2015

Elizabeth Holmes Discusses Theranos at WSJDLive 2015 Elizabeth Holmes Discusses Theranos at WSJDLive 2015 At the WSJDLive 2015 conference, Theranos founder and CEO Elizabeth Holmes discusses her company's proprietary technologies, the FDA's inspection of its facilities, and the assertion that her company was too quick to market its products.